[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638546":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":37,"locations":43,"responsibleParty":73,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":37,"enrollmentInfo":90,"targetDuration":37,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":46,"whyStopped":37,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Cambridge University Hospitals NHS Foundation Trust","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose interleukin-2 at dose 1.5MIU","EXPERIMENTAL","Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Dose of 1.5MIU will be used for all daily and, if needed, weekly doses",[13,14],"Drug: Interleukin-2 (Aldesleukin)","Procedure: Standard care",{"label":16,"type":10,"description":17,"interventionNames":18},"Low dose interleukin-2 at dose 2.0MIU","Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Dose of 2.0MIU will be used for all daily and, if needed, weekly doses",[14,13],{"label":20,"type":21,"description":22,"interventionNames":23},"Control","ACTIVE_COMPARATOR","Standard of care treatment",[14],[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Interleukin-2 (Aldesleukin)","5 sequential days of treatment (1.5MIU\u002Fday subcutaneously) and, if needed, 1.5MIU\u002Fweek doses until CABG surgery completed",[9],[31],"1.5MIU",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"PROCEDURE","Standard care","Standard care for patients with coronary artery disease undergoing CABG surgery",[20,9,16],null,{"type":26,"name":27,"description":39,"armGroupLabels":40,"otherNames":41},"5 sequential days of treatment (2.0MIU\u002Fday subcutaneously) and, if needed, 2.0MIU\u002Fweek doses until CABG surgery completed",[16],[42],"2.0MIU",[44,65],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Royal Papworth Hospital NHS Foundation Trust","RECRUITING","Cambridge","Cambridgeshire","CB2 0AY","United Kingdom","UK",{"type":53,"coordinates":54},"Point",[55,56],0.11667,52.2,{"lat":56,"lon":55},[59],{"name":60,"role":61,"phone":62,"phoneExt":63,"email":64},"Ali Al-Hadithi, MB BChir","CONTACT","Royal Papworth Hospital NHS Fo","01223768678","abaka2@cam.ac.uk",{"facility":66,"status":46,"city":47,"state":48,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Addenbrooke's Hospital","CB2 0QQ",{"type":53,"coordinates":69},[55,56],{"lat":56,"lon":55},[72],{"name":60,"role":61,"phone":63,"phoneExt":37,"email":64},{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"PRINCIPAL_INVESTIGATOR","Tian Zhao","BHF Intermediate Fellow",[78],{"name":79,"class":80},"Royal Papworth Hospital","OTHER_GOV","100638546","low-dose-interleukin-2-after-myocardial-infarction-to-investigate-effects-on-tissue-resident-regulatory-t-cells-100638546",false,"NCT07610538","Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells","Leuk-ALIVE","Inclusion Criteria:\n\n* Aged over 18 years old\n* Undergoing CABG surgery\n\nExclusion Criteria:\n\n* Critical left main stem coronary disease\n* Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)\n* Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission\n* Non-sustained ventricular tachycardia of \\>10 beats in the last 48 hours\n* Autoimmune disease\n* Any regular immunosuppressive treatment \\[Inhaled or topical steroids are permissible\\]\n* Known active hepatic disease or alanine aminotransferase (ALT) \\> 3xULN\n* Severe chronic kidney disease (defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2)\n* Allergy or intolerance to aldesleukin\n* Signs and symptoms of active infection\n* History of human immunodeficiency virus (HIV), hepatitis B or C\n* Current malignancy requiring active treatment\n* Vaccine within 4 weeks prior to screening\n* Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and\u002For bilateral oophorectomy)\n* Women who are breast-feeding\n* Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study","ALL","18 Years",{"count":91,"type":92},24,"ESTIMATED","INTERVENTIONAL",[95],"NA","The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell\u002F-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.",[98,99,100],"Coronary Artery Disease","Myocardial Infarction (MI)","CABG",[102,103,104,105,100,106],"Interleukin-2","IL-2","MI","Myocardial infarction","Coronary artery bypass graft","2026-05-20",{"date":109,"type":110},"2026-05-28","ACTUAL",{"date":112,"type":110},"2026-03-31",{"date":114,"type":92},"2028-12-01",{"name":5,"class":6},2]